Previous research trials

  • EARLY study – Protocol 54861911ALZ2003 – An Efficacy and Safety Study of JNJ-54861911 in Participants who are Asymptomatic at Risk for Developing Alzheimer’s Dementia.  https://clinicaltrials.gov/ct2/show/NCT02569398?term=JNJ-54861911&rank=5
  • HREC No: A15734 – The Melanoma and Vitamin D Study (MELD)
  • Unmet needs in dermatology: Delay in treatment and diagnosis of hidradenitis suppurativa, a worldwide collaborative study.
  • An observational, multi centre disease registry to evaluate clinical practice trends and outcomes in adult patients with hidradenitis suppurativa.
  • (NAVIGATE-AD)Protocol I7X-MC-LLCF – Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer’s Disease.  https://clinicaltrials.gov/ct2/show/NCT02791191?term=LY3202626&cond=Alzheimer+Disease&rank=1
  • A phase 3 multi centre study of the safety and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa.
  • HREC No: P1481: Skin Tumours in Allograft Recipients (STAR).
  • CTX-4430-AV-201: A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.
  • ALIGN, a multi-country, cross sectional study to determine patient specific and general beliefs towards medication and their treatment compliance to selected systemic therapies in chronic inflammatory diseases (IMID)
  • Janssen TMC435-TiDP-C205: A Phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including Peginterferon alfa-2a and Ribavirin in treatment-naïve genotype 1 hepatitis C-infected subjects.
  • Janssen TMC435-TiDP16-C206 A phase IIb, randomized, double-blind, placebo-controlled trial to investigate the efficacy, tolerability, safety and pharmacokinetics of TMC435 as part of a treatment regimen including pegIFN alfa 2a and ribavirin in HCV genotype 1 infected subjects who failed to respond or relapsed following at least 1 course of PegIFN alfa 2a and ribavirin therapy.
  • Amgen Protocol 20101147: A randomised, double-blind, placebo-controlled, single-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical effects of AMG 811 in subjects with moderate to severe psoriasis.
  • Anacor AN2898-AD-202 A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Bilateral Study on the Safety and Efficacy of AN2898 and AN2728 in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
  • HREC/10/QPAH/28 Investigating the hyperaemic response to topical anaesthesia in patients with rosacea.
  • Amgen AMG 139 A randomised, double-blind, placebo-controlled, ascending single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 139 in healthy subjects and subjects with moderate to severe psoriasis.
  • Bristol-Myers Squibb IM119013 A phase 2a, randomized, double blind, placebo controlled study to evaluate the clinical efficacy, safety, and pharmacokinetics of three different doses of MS-582949 given orally to subjects with moderate to severe plaque psoriasis.
  • Genentech, Inc. SHH4476g A pivotal phase 2, multicentre, single arm, two cohort trial evaluating the efficacy and safety of GDC-0449 in patients with advanced Basal Cell Carcinoma.
  • Clinuvel CUV011 A multicentre, randomized, double blind, placebo controlled, phase 2 study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of CUV1647 for the prophylactic treatment of precancerous skin lesions of the head, forearms and hands in immune compromised organ transplant patients.
  • Peplin PEP005 -013 A Phase I, pharmacokinetic study to evaluate the extent of systemic absorption of PEP005, when applied as 0.05% PEP005 Topical Gel to a 100 cm2 (5 cm x 20 cm) contiguous AK treatment area on the dorsal fore-arm.
  • Peplin PEP005-008  Multi-centre, open label study to determine the safety and efficacy of PEP 005 0.05% gel in patients with Cutaneous Squamous Cell Carcinoma in situ (SCCIS, Bowen’s Disease)
  • Peplin PEP005-001 A multi-centre, randomized, double-blind, parallel-group, vehicle-controlled study to determine the safety of PEP005 0.0025%, 0.01% and 0.05% gel with two schedules, Day 1 and Day 2 or Day 1 and Day 8 applications to actinic keratoses.
  • Peplin PEP005-003 A multi-centre, randomized, double-blind, parallel-group, vehicle-controlled study to determine the safety of PEP005 0.0025%, 0.01% and 0.05% gel with two schedules, Day 1 and Day 2 or Day 1 and Day 8 applications to superficial basal cell carcinoma.
  • Peplin PEP005-002 A multi-centre, randomized, double-blind, parallel-group, vehicle-controlled study to determine the safety of PEP005 0.0025%, 0.01% and 0.05% gel with two schedules, Day 1 and Day 2 or Day 1 and Day 8 applications to nodular basal cell carcinoma.
  • Peplin PEP005-015 A multicentre, randomised, double-blind, vehicle-controlled, dose-ranging study to evaluate the safety and efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel when used to treat actinic keratoses on the head (face or Scalp).
  • Peplin PEP005-007 An open label, multi-centre, dose escalation, cohort study to determine the optimal tolerated regime and safety of PEP005 Topical Gel when applied to a 25cm contiguous actinic keratoses treatment area on the face or face and scalp.
  • Wyeth 0468H1-407-WW A randomized, open–label study to compare the rate of new non-melanoma skin cancer in maintenance renal allograft recipients converted to a sirolimus-based regimen versus continuation of a calcineurin inhibitor-based regimen.
  • Galderma RD.03.spr.40027 Assessment of the efficacy and safety of three concentraions: 1%, 0.3%, 0.1% of CD5024 cream once daily and CD5024 1% cream twice daily, versus its vehicle and versus metronidazole 0.75% cream (Rozex) in patients with moderate to severe papulo-pustular rosacea over 12 weeks.
  • Galderma RD.03.spr.40037 An exploratory study to evaluate relapses following an initial 12 weeks dose range study with CD5024 cream versus its vehicle and versus metronidazole 0.75% cream papulo-pustular rosacea – a 6 months follow up treatment free study.
  • Corgentech 110_02P “A Phase 1/2 Multicenter, Randomized, Placebo-Controlled Double-Blind, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Regiments of a Candidate Topical NF-kappaB Decoy in the Treatment of Adults with Mild to Moderate Atopic Dermatitis.”
  • 3M Imiquimod trial 1413 “An open-labelled study to evaluate safety and long term clinical efficacy of Imiquimod 5% cream applied once daily, seven days per week for six weeks in the treatment of superficial basal cell carcinoma.”
  • 3M Imiquimod trial 1431 “An open-labelled multi-centre study to evaluate the efficacy and safety of Imiquimod 5% cream in subjects with multiple superficial basal cell carcinoma lesions.”
  • Photocure Photo Dynamic Therapy trial PCT308/00“ Multi-centre phase III, double blind study of photodynamic therapy (PDT) with Metvix 160mg/g cream in comparison to PDT with placebo in patients with primary nodular basal cell carcinoma.”
  • Transscan Melanoma Electrical Impedance study  “Melanoma and dysplastic naevus diagnosis by means of electrical impedence measurements of normal and dysplastic skin using the TS2000M.”
  • SkyePharma SKY4007-001 Therapy Trial “A Phase 3, Randomised, Double-Blind, Vehicle-Controlled, Study to Evaluate the Safety and Efficacy of SKY4007 in Subjects with Actinic Keratoses.”
  • “An open-label study to investigate the efficacy and safety of imiquimod 5% cream applied topically as an adjunct to curettage for the treatment of non-aggressive nodular basal cell carcinoma.”
  • “Alternative splicing of GLI1 and its role in tumorigenesis.”
  • “A randomized, Double Blind, Placebo-controlled, Parallel group, Multicenter, 52 week study to evaluate the efficacy and safety of transdermal patches delivering 150 or 300 ug/day Testosterone in Menopausal Women with low libido not receiving Systemic Estrogen Progestin Therapy.”
  • HREC/13/QPAH/693 Improved topical drug delivery to healthy and diseased skin using elongated microparticles. Protocol Number: TP003
  • A Single-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics of Various Concentrations of Topical SM04554 Solution in Male Subjects with Androgenetic Alopecia
  • An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single Dose Brodalumab Pharmacokinetics in Subjects with Moderate to Severe Plaque Psoriasis

Find out more about current research trials.